EZH2 and Hepatic fibrosis: The EZH2 inhibitor EPZ‐6438 rescues EZH2‐mediated KLF14 downregulation, which transactivates PPARγ expression, converts the activated HSCs to the quiescent phenotype and induces apoptosis, and therefore alleviating liver fibrosis.